Phase I, randomised, open label, 3-period crossover study in healthy male subjects to investigate the effect of food on the pharmacokinetics of AZD8931 and to investigate the safety and tolerability of AZD8931.

Inclusion Criteria:

• Provision of written informed consent
• Body mass index (BMI) between 19 and 30 kg/m2

Exclusion Criteria:

• Use of any prescribed or non-prescribed medication (including analgesics, herbal remedies, vitamins and minerals) during the two weeks prior to the first administration of investigational product
• Administration of another investigational medicinal product in the 3 months before the start of dosing in this study
• Definite or suspected clinically relevant personal history of adverse drug reactions, or drug hypersensitivity